introducing GLP-1 agonists into our therapeutic armamentarium for HS would not be a far stretch and may have synergistic benefits when given with our other standard HS medications such as biologics
Deane AM, Chapman MJ, Horowitz M
More recently, research on this new GLP-1 analog has gradually expanded into other areas, including diabetes, chronic kidney disease, cardiovascular disease, NASH, and Alzheimers disease (Knudsen and Lau, 2019)
Your dose may increase during treatment, but your monthly price remains fixed at the starting tier you selectensuring cost predictability regardless of therapeutic dosing adjustments
These higher doses are not available in all regions, and suitability depends on individual response and clinical advice